The N-MOmentum study - a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results

被引：0

作者：

Cree, B. ^{[1
]}

Bennett, J. ^{[2
]}

Kim, H. J. ^{[3
]}

Weinshenker, B. ^{[4
]}

Pittock, S. ^{[4
]}

Wingerchuk, D. ^{[5
]}

Fujihara, K. ^{[6
]}

Paul, F. ^{[7
,8
,9
]}

Cutter, G. ^{[10
]}

Marignier, R. ^{[11
]}

Green, A. ^{[1
]}

Aktas, O. ^{[12
]}

Hartung, H. -P. ^{[12
]}

Lublin, F. ^{[13
]}

Mealy, M. ^{[14
]}

Drappa, J. ^{[14
]}

Barron, G. ^{[15
]}

Madani, S. ^{[14
]}

Shi, D. ^{[14
]}

Cimbora, D. ^{[14
]}

Rees, W. ^{[14
]}

Ratchford, J. ^{[14
]}

Katz, E. ^{[14
]}

机构：

[1] Univ Calif San Francisco, Weill Inst Neurosci, Neurol, San Francisco, CA 94143 USA

[2] Univ Colorado, Sch Med, Neurol & Ophthalmol, Denver, CO USA

[3] Res Inst & Hosp Natl Canc Ctr, Goyang, South Korea

[4] Mayo Clin, Rochester, MN USA

[5] Mayo Clin, Scottsdale, AZ USA

[6] Fukushima Med Univ, Sch Med, Fukushima, Japan

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Humboldt Univ, Freie Univ Berlin, Berlin, Germany

[9] Berlin Inst Hlth, Berlin, Germany

[10] Univ Alabama Birmingham, Birmingham, AL USA

[11] Hosp Civils Lyon, Lyon, France

[12] Heinrich Heine Univ, Dusseldorf, Germany

[13] Mt Sinai Hosp, New York, NY 10029 USA

[14] Viela Bio, Gaithersburg, MD USA

[15] Astrazeneca, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

139

引用

页码：42 / 44

页数：3

共 50 条

[1] The N-MOmentum Study-A Randomised, Placebo-Controlled, Double-Blind Trial of Inebilizumabfor Neuromyelitis Optica Spectrum Disorder: Randomised Controlled Period and Open-label Extension Results
Kim, H. J.
Bennett, J. L.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H-P
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP37 - NP38
[2] Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Cree, Bruce A. C.
Bennett, Jeffrey L.
Kim, Ho Jin
Weinshenker, Brian G.
Pittock, Sean J.
Wingerchuk, Dean M.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary R.
Marignier, Romain
Green, Ari J.
Aktas, Orhan
Hartung, Hans-Peter
Lublin, Fred D.
Drappa, Jorn
Barron, Gerard
Madani, Soraya
Ratchford, John N.
She, Dewei
Cimbora, Daniel
Katz, Eliezer
Shuey, Neil
Milanov, Ivan
Kaprelyan, Ara
Tarnev, Ivaylo
Haralanov, Lyubomir
Carruthers, Robert
Munoz, Mario
Quinones, Jairo
Vargas, Jose
Rodriguez, Jesus
Nytrova, Petra
Vachova, Marta
Mares, Jan
Haldre, Sulev
Gross-Paju, Katrin
Ziemssen, Tjalf
Zettl, Uwe Klaus
Klotz, Luisa
Bergh, Florian Then
Lau, Alexander
Dioszeghy, Peter
Satori, Maria
Vecsei, Laszlo
Achiron, Anat
Karni, Arnon
Vaknin-Dembinsky, Adi
Saida, Takahiko
Misu, Tatsuro
Baba, Masayuki
LANCET, 2019, 394 (10206): : 1352 - 1363
[3] The N-MOmentum Trial Of Inebilizumab For Neuromyelitis Optica Spectrum Disorder: Randomized Controlled Period And Long-term Open-label Extension
Cree, B. A.
Bennett, J. L.
Kim, H.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 10 - 11
[4] Inebilizumab prevents neuromyelitis optica spectrum disorder disability: outcomes from the N-MOmentum randomised, placebo-controlled, double-masked trial
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Green, A.
Aktas, O.
Hartung, H. -P.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 896 - 898
[5] Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
Cree, Bruce A. C.
Kim, Ho Jin
Weinshenker, Brian G.
Pittock, Sean J.
Wingerchuk, Dean M.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary R.
Marignier, Romain
Green, Ari J.
Aktas, Orhan
Hartung, Hans -Peter
She, Dewei
Rees, William
Smith, Michael
Cimbora, Daniel
Katz, Eliezer
Bennett, Jeffrey L.
LANCET NEUROLOGY, 2024, 23 (06): : 588 - 602
[6] Sensitivity analyses of time to adjudicated attacks in the N-MOmentum study, a randomised, placebo-controlled, double-masked trial in patients with neuromyelitis optica spectrum disorder
Cree, B. A. C.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H. -P.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 928 - 929
[7] Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension
Cree, B. A. C.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H-P.
Lublin, F.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
NEUROLOGY, 2020, 94 (15)
[8] The N-MOmentum Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Long-term, Open-label Efficacy and Safety Update
Cree, B. A.
Bennett, J. L.
Weinshenker, B. G.
Wingerchuk, D.
Paul, F.
Kim, H.
Pittock, S.
Fujihara, K.
Cutter, G.
Marignier, R.
Aktas, O.
Hartung, H.
Green, A. J.
Drappa, J.
She, D.
Cimbora, D.
Rees, W.
Smith, M.
Ratchford, J. N.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 83 - 83
[9] Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension
Sinha, Smeeta
Nigwekar, Sagar U.
Brandenburg, Vincent
Gould, Lisa J.
Serena, Thomas E.
Moe, Sharon M.
Aronoff, George R.
Chatoth, Dinesh K.
Hymes, Jeffrey L.
Carroll, Kevin J.
Alperovich, Gabriela
Keller, Laurence H.
Perello, Joan
Gold, Alex
Chertow, Glenn M.
ECLINICALMEDICINE, 2024, 75
[10] Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Traboulsee, Anthony
Greenberg, Benjamin M.
Bennett, Jeffrey L.
Szczechowski, Lech
Fox, Edward
Shkrobot, Svitlana
Yamamura, Takashi
Terada, Yusuke
Kawata, Yuichi
Wright, Padraig
Gianella-Borradori, Athos
Garren, Hideki
Weinshenker, Brian G.
LANCET NEUROLOGY, 2020, 19 (05): : 402 - 412

← 1 2 3 4 5 →